| 1 |
2022 |
Abdelrahman K. A. A. Salama, Marija V. Trkulja, Emilio Casanova, Iris Z. Uras. Targeted Protein Degradation: Clinical Advances in the Field of Oncology, International Journal of Molecular Sciences. 2022; 23: 15440.
https://doi.org/10.3390/ijms232315440 |
| 2 |
2023 |
Kristina Viktorsson, Thorsten Rieckmann, Maximilian Fleischmann, Markus Diefenhardt, Stephanie Hehlgans, Franz Rödel. Advances in molecular targeted therapies to increase efficacy of (chemo)radiation therapy, Strahlentherapie und Onkologie. 2023; 199: 1091.
https://doi.org/10.1007/s00066-023-02064-y |
| 3 |
2024 |
Soohyun Lee, Hwa‐Ryeon Kim, Yaejin Woo, Jiyoung Kim, Han Wool Kim, Ji Youn Park, Beomseon Suh, Yuri Choi, Jungmin Ahn, Je Ho Ryu, Jae‐Seok Roe, Jaewhan Song, Song Hee Lee. UBX‐390: A Novel Androgen Receptor Degrader for Therapeutic Intervention in Prostate Cancer, Advanced Science. 2024; 11: 2400398.
https://doi.org/10.1002/advs.202400398 |
| 4 |
2022 |
O. A. Koroleva, Yu. V. Dutikova, A. V. Trubnikov, F. A. Zenov, E. V. Manasova, A. A. Shtil, A. V. Kurkin. PROTAC: targeted drug strategy. Principles and limitations, Russian Chemical Bulletin. 2022; 71: 2310.
https://doi.org/10.1007/s11172-022-3659-z |
| 5 |
2023 |
Rodrigo Sánchez Bayona, Manuel Alva Bianchi. Luminal breast cancer treatment beyond cell cycle inhibitors, Revisiones en Cáncer. 2023;
https://doi.org/10.20960/revcancer.00027 |
| 6 |
2023 |
Carmen Avendaño, J. Carlos Menéndez. 2023; 637.
https://doi.org/10.1016/B978-0-12-818549-0.00012-1 |
| 7 |
2024 |
Luís A. R. Carvalho, Bárbara B. Sousa, Daniel Zaidman, Hannah Kiely‐Collins, Gonçalo J. L. Bernardes. Design and Evaluation of PROTACs Targeting Acyl Protein Thioesterase 1, ChemBioChem. 2024; 25: e202300736.
https://doi.org/10.1002/cbic.202300736 |
| 8 |
2024 |
Jun Xia, James K.S. Norris, May-Li MacKinnon, Sam Butterworth. Proteolysis Targeting Chimeras (PROTACs): An Innovative Strategy for Targeted Protein Degradation and Disease Treatment, International Journal of Drug Discovery and Pharmacology. 2024; 100015.
https://doi.org/10.53941/ijddp.2024.100015 |
| 9 |
2023 |
Lara J. Bou Malhab, Habiba Alsafar, Saleh Ibrahim, Mohamed Rahmani. PROTACs: Walking through hematological malignancies, Frontiers in Pharmacology. 2023; 14: 1086946.
https://doi.org/10.3389/fphar.2023.1086946 |
| 10 |
2023 |
, Revolutionizing Drug Targeting Strategies: Integrating Artificial Intelligence and Structure-Based Methods in PROTAC Development, Pharmaceuticals. 2023; 16: 1649.
https://doi.org/10.3390/ph16121649 |
| 11 |
2023 |
Abhenil Mittal, Consolacion Molto Valiente, Faris Tamimi, Ilana Schlam, Sarah Sammons, Sara M. Tolaney, Paolo Tarantino. Filling the Gap after CDK4/6 Inhibitors: Novel Endocrine and Biologic Treatment Options for Metastatic Hormone Receptor Positive Breast Cancer, Cancers. 2023; 15: 2015.
https://doi.org/10.3390/cancers15072015 |
| 12 |
2024 |
Simon C. C. Lucas, Afshan Ahmed, S. Neha Ashraf, Argyrides Argyrou, Matthias R. Bauer, Gian Marco De Donatis, Sylvain Demanze, Frederik Eisele, Lucia Fusani, Andreas Hock, Ganesh Kadamur, Shuyou Li, Abigail Macmillan-Jones, Iacovos N. Michaelides, Christopher Phillips, Marie Rehnström, Magdalena Richter, Monica C. Rodrigo-Brenni, Fiona Shilliday, Peng Wang, R. Ian Storer. Optimization of Potent Ligands for the E3 Ligase DCAF15 and Evaluation of Their Use in Heterobifunctional Degraders, Journal of Medicinal Chemistry. 2024; 67: 5538.
https://doi.org/10.1021/acs.jmedchem.3c02136 |
| 13 |
2024 |
Inés Montoya-Novoa, José Luis Gardeazábal-Torbado, Andrea Alegre-Martí, Pablo Fuentes-Prior, Eva Estébanez-Perpiñá. Androgen receptor post-translational modifications and their implications for pathology, Biochemical Society Transactions. 2024; 52: 1673.
https://doi.org/10.1042/BST20231082 |
| 14 |
2022 |
Claudia J. Diehl, Alessio Ciulli. Discovery of small molecule ligands for the von Hippel-Lindau (VHL) E3 ligase and their use as inhibitors and PROTAC degraders, Chemical Society Reviews. 2022; 51: 8216.
https://doi.org/10.1039/D2CS00387B |
| 15 |
2022 |
Zi Liu, Mingxing Hu, Yu Yang, Chenghao Du, Haoxuan Zhou, Chengyali Liu, Yuanwei Chen, Lei Fan, Hongqun Ma, Youling Gong, Yongmei Xie. An overview of PROTACs: a promising drug discovery paradigm, Molecular Biomedicine. 2022; 3: 46.
https://doi.org/10.1186/s43556-022-00112-0 |
| 16 |
2023 |
Miroslav Peřina, Márton A. Kiss, Gergő Mótyán, Eva Szczyrbová, Martin Eliáš, Vladimír Študent jr, Daniela Kurfürstová, Markéta Kovalová, Lukáš Mada, Jan Bouchal, Éva Frank, Radek Jorda. A-ring-fused pyrazoles of dihydrotestosterone targeting prostate cancer cells via the downregulation of the androgen receptor, European Journal of Medicinal Chemistry. 2023; 249: 115086115086.
https://doi.org/10.1016/j.ejmech.2023.115086 |
| 17 |
2023 |
Mayuri P Kannan, Sarojini Sreeraman, Chaitanya S Somala, Raja BS Kushwah, Saravanan K Mani, Vickram Sundaram, Anand Thirunavukarasou. Advancement of Targeted Protein Degradation Strategies As Therapeutics for Undruggable Disease Targets, Future Medicinal Chemistry. 2023; 15: 867.
https://doi.org/10.4155/fmc-2023-0072 |
| 18 |
2022 |
Sinan Ma, Jianai Ji, Yuanyuan Tong, Yuxuan Zhu, Junwei Dou, Xian Zhang, Shicheng Xu, Tianbao Zhu, Xiaoli Xu, Qidong You, Zhengyu Jiang. Non-small molecule PROTACs (NSM-PROTACs): Protein degradation kaleidoscope, Acta Pharmaceutica Sinica B. 2022; 12: 2990.
https://doi.org/10.1016/j.apsb.2022.02.022 |
| 19 |
2024 |
Eduardo Silva Ramos, Todd M. Greco, Ileana M. Cristea, Erich E. Wanker. 2024; 159.
https://doi.org/10.1016/B978-0-323-95672-7.00016-9 |
| 20 |
2022 |
Hang Luo, Li Wu, Yujian He, Chong Qin, Xinjing Tang. Major Advances in Emerging Degrader Technologies, Frontiers in Cell and Developmental Biology. 2022; 10: 921958.
https://doi.org/10.3389/fcell.2022.921958 |
| 21 |
2024 |
Peter D. Zang, Allen Seylani, Evan Y. Yu, Tanya B. Dorff. PROTACing the androgen receptor and other emerging therapeutics in prostate cancer, Expert Review of Anticancer Therapy. 2024; 24: 829.
https://doi.org/10.1080/14737140.2024.2379913 |
